Deep Brain Stimulation Devices Market Size

Deep Brain Stimulation Devices Market Analysis

The deep brain stimulation (DBS) devices market is expected to register a CAGR of nearly 12.5% during the forecast period.

The COVID-19 pandemic is expected to have a significant impact on market growth. The pandemic restrictions worsened motor and psychiatric symptoms in patients suffering from neurological disorders treated with deep brain stimulation (DBS) devices. The pandemic worsened the burden of brain disorders and surged the chronic stress related to deep brain stimulation management. According to the study published by the Neurologia Journal in August 2021, during the pandemic, the prevalence of COVID-19 in Parkinson's patients was 11.28%. However, COVID-19 in Parkinson's patients undergoing Deep Brain Stimulation (DBS) was 18.18%. Thus, the worsening of neurological disorders amongst COVID-19 patients encouraged the prominent players to develop novel DBS devices, significantly impacting the market growth. For instance, according to the article published by the Nature Journal in October 2022, the pandemic accelerated the adoption of DBS teleprogramming in countries like Hungary, present in the European region.

Furthermore, the prominent players actively assisted patients requiring DBS treatment during the pandemic. For instance, in March 2021, Abbott launched the NeuroSphere Virtual Clinic, allowing patients to connect with physicians and remotely safeguard DBS devices' proper settings and functionality. The US-FDA-approved NeuroSphere Virtual Clinic enhanced patient access to optimal treatment for patients suffering from chronic movement disorders who could not go to the healthcare clinic because of COVID-19 lockdowns. Therefore, looking at the overall scenario, the COVID-19 pandemic worsened the situation of patients suffering from neurological disorders. However, the market registered stable growth due to the increased adoption of remote solutions and is expected to witness significant growth during the forecast period.

DBS is a widely used treatment for advanced Parkinson's disease (PD), essential tremors, and dystonia. Over the past few years, in addition to the extension of its clinical applications, there has been tremendous growth in deep brain stimulation technology. The major factors driving the development of the market include the rapidly aging population, which is leading to risk and high prevalence of neurological disorders, growing demand for the devices due to the rising popularity of minimally invasive procedures, and availability of technologically advanced deep brain stimulation devices.

The rising prevalence of various neurological disorders like Epilepsy is projected to drive the market growth during the forecast period. For instance, according to the key facts published by the WHO in February 2023, approximately 50 million people worldwide have Epilepsy, making it one of the most common neurological diseases globally. As per the same source, about 80% of people with Epilepsy live in low- and middle-income countries. Furthermore, the prominent players are actively participating in the launch of advanced DBS devices in various countries worldwide, which is also burgeoning the market growth. For instance, in August 2022, Medtronic Private Limited, a subsidiary of Medtronic plc, launched the SenSight directional lead system for DBS therapy to treat movement disorders and Epilepsy in India. Similarly, in December 2022, Medtronic plc launched its DBS system, Percept PC, in South Korea to treat tremors and Parkinson's patients. Percept PC is equipped with BrainSense technology to provide electrical DBS treatment to neurological patients.

Therefore, the market is expected to grow significantly during the forecast period due to the abovementioned factors. However, risks associated with deep brain stimulation procedures and the implementation of stringent government policies are expected to hamper market growth during the forecast period.